Propranolol: A 50-year historical perspective
Propranolol is a beta-adrenergic receptor antagonist that was developed by the British scientist Sir James Black primarily for the treatment of angina pectoris, more than 50 years ago. It was not long before several other cardiovascular as well as noncardiovascular therapeutic uses of propranolol we...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2019-01-01
|
| Series: | Annals of Indian Academy of Neurology |
| Subjects: | |
| Online Access: | http://www.annalsofian.org/article.asp?issn=0972-2327;year=2019;volume=22;issue=1;spage=21;epage=26;aulast=Srinivasan |
| _version_ | 1819078771390545920 |
|---|---|
| author | A V Srinivasan |
| author_facet | A V Srinivasan |
| author_sort | A V Srinivasan |
| collection | DOAJ |
| description | Propranolol is a beta-adrenergic receptor antagonist that was developed by the British scientist Sir James Black primarily for the treatment of angina pectoris, more than 50 years ago. It was not long before several other cardiovascular as well as noncardiovascular therapeutic uses of propranolol were discovered. Propranolol soon became a powerful tool for physicians in the treatment of numerous conditions such as hypertension, cardiac arrhythmias, myocardial infarction, migraine, portal hypertension, anxiety, essential tremors, hyperthyroidism, and pheochromocytoma. Owing to its action at multiple receptor sites, propranolol exerts several central and peripheral effects and is therefore useful in various conditions. Right from reduction in postmyocardial mortality to control of anxiety in performers, propranolol plays an important role in a plethora of medical conditions. Interestingly, even today, newer indications of this age-old drug are being discovered. Moreover, propranolol treatment has been found to be cost-effective when compared to other corresponding treatment options for individual indications. In this article, we attempt to recount the journey of propranolol right from its inception to the present day. |
| first_indexed | 2024-12-21T19:18:23Z |
| format | Article |
| id | doaj.art-41cc0d0d23cb4543ba5aaa418be04861 |
| institution | Directory Open Access Journal |
| issn | 0972-2327 1998-3549 |
| language | English |
| last_indexed | 2024-12-21T19:18:23Z |
| publishDate | 2019-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Annals of Indian Academy of Neurology |
| spelling | doaj.art-41cc0d0d23cb4543ba5aaa418be048612022-12-21T18:53:00ZengWolters Kluwer Medknow PublicationsAnnals of Indian Academy of Neurology0972-23271998-35492019-01-01221212610.4103/aian.AIAN_201_18Propranolol: A 50-year historical perspectiveA V SrinivasanPropranolol is a beta-adrenergic receptor antagonist that was developed by the British scientist Sir James Black primarily for the treatment of angina pectoris, more than 50 years ago. It was not long before several other cardiovascular as well as noncardiovascular therapeutic uses of propranolol were discovered. Propranolol soon became a powerful tool for physicians in the treatment of numerous conditions such as hypertension, cardiac arrhythmias, myocardial infarction, migraine, portal hypertension, anxiety, essential tremors, hyperthyroidism, and pheochromocytoma. Owing to its action at multiple receptor sites, propranolol exerts several central and peripheral effects and is therefore useful in various conditions. Right from reduction in postmyocardial mortality to control of anxiety in performers, propranolol plays an important role in a plethora of medical conditions. Interestingly, even today, newer indications of this age-old drug are being discovered. Moreover, propranolol treatment has been found to be cost-effective when compared to other corresponding treatment options for individual indications. In this article, we attempt to recount the journey of propranolol right from its inception to the present day.http://www.annalsofian.org/article.asp?issn=0972-2327;year=2019;volume=22;issue=1;spage=21;epage=26;aulast=SrinivasanAnxietybeta-blockermyocardial infarctionportal hypertensionpropranolol |
| spellingShingle | A V Srinivasan Propranolol: A 50-year historical perspective Annals of Indian Academy of Neurology Anxiety beta-blocker myocardial infarction portal hypertension propranolol |
| title | Propranolol: A 50-year historical perspective |
| title_full | Propranolol: A 50-year historical perspective |
| title_fullStr | Propranolol: A 50-year historical perspective |
| title_full_unstemmed | Propranolol: A 50-year historical perspective |
| title_short | Propranolol: A 50-year historical perspective |
| title_sort | propranolol a 50 year historical perspective |
| topic | Anxiety beta-blocker myocardial infarction portal hypertension propranolol |
| url | http://www.annalsofian.org/article.asp?issn=0972-2327;year=2019;volume=22;issue=1;spage=21;epage=26;aulast=Srinivasan |
| work_keys_str_mv | AT avsrinivasan propranolola50yearhistoricalperspective |